TRIM59 and Notch Signaling in Pancreatic Cancer Resistance
Author Information
Author(s): Chen Shiyu, He Zhiwei, Cai Kun, Zhang Yan, Zhu Hongyan, Pang Chong, Zhang Jiaqi, Wang Dong, Xu Xundi
Primary Institution: South China Hospital, Medical School, Shenzhen University
Hypothesis
TRIM59 contributes to gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway.
Conclusion
TRIM59 promotes gemcitabine resistance in pancreatic cancer by stabilizing RBPJ and activating Notch signaling.
Supporting Evidence
- TRIM59 levels were increased in pancreatic cancer and correlated with poor prognosis.
- TRIM59 facilitated gemcitabine resistance in pancreatic cancer cells in vitro and in vivo.
- TRIM59 interacted with RBPJ and stabilized it through K63-linked ubiquitination.
Takeaway
This study found that a protein called TRIM59 helps pancreatic cancer cells resist a common treatment called gemcitabine, making it harder to treat the cancer.
Methodology
The study involved clinical data analysis, in vitro and in vivo experiments, and various assays including RT-qPCR, western blotting, and immunohistochemistry.
Potential Biases
Potential biases may arise from the selection of clinical samples and the experimental conditions used.
Limitations
The study primarily focuses on the role of TRIM59 and may not account for other factors influencing gemcitabine resistance.
Participant Demographics
Patients with pancreatic cancer, specifically those undergoing gemcitabine treatment.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website